A phase II study of doxifluridine in elderly patients with advanced gastric cancer: The Japan Clinical Oncology Group study (JCOG 9410)

被引：9

作者：

Ikeda, N ^{[1
]}

Shimada, Y ^{[1
]}

Ohtsu, A ^{[1
]}

Boku, N ^{[1
]}

Tsuji, Y ^{[1
]}

Saito, H ^{[1
]}

Koizumi, W ^{[1
]}

Iwase, H ^{[1
]}

Yoshida, S ^{[1
]}

Fukuda, H ^{[1
]}

机构：

[1] Mitoyo Gen Hosp, Dept Internal Med, Kagawa, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 32卷 / 03期

关键词：

doxifluridine; elderly patients; gastric cancer;

D O I：

10.1093/jjco/hyf022

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: A previous phase 11 study of doxifluridine in non-elderly patients with advanced gastric cancer demonstrated a favorable survival with mild toxicity, despite a low response rate. The objectives of this study were to evaluate efficacy and feasibility of this agent for elderly patients. Methods: This study protocol required elderly patients, aged 76-80 years, with advanced gastric cancer and having no prior chemotherapy. Doxifluridine, at a dose of 1400 mg/m(2)/day, was administered for four consecutive days followed by a 10-day rest. Results: Between October 1994 and March 1998, 18 patients were registered. The study was then closed because of poor accrual. Toxicity was moderate; three patients suffered from grade 3 anemia and one patient each had grade 3 thrombocytopenia, nausea/vomiting and grade 4 diarrhea. There was one partial response, seven with no change and 10 with progressive disease, yielding a response rate of 5.6%. The median progression-free survival and median survival time for the 18 patients were 55 and 164 days, respectively, with a 1-year survival rate of 5.6%. Conclusions: Although the number of patients was too small to draw any definitive conclusions, this study failed to demonstrate the survival advantage of doxifluridine.

引用

页码：90 / 94

页数：5